{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:17:03Z","timestamp":1792815423483,"version":"4.5.0"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007162","name":"Guangdong Science and Technology Department","doi-asserted-by":"publisher","award":["2017A020215183"],"award-info":[{"award-number":["2017A020215183"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010096","name":"Southern Medical University","doi-asserted-by":"publisher","award":["LC2016ZD027"],"award-info":[{"award-number":["LC2016ZD027"]}],"id":[{"id":"10.13039\/501100010096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2018B030311042"],"award-info":[{"award-number":["2018B030311042"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02664","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T09:46:44Z","timestamp":1573552004000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":326,"title":["Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies"],"prefix":"10.3389","volume":"10","author":[{"given":"Xinjie","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanfang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19 negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med."},{"key":"B4","first-page":"4817","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume-title":"Blood.","author":"Brentjens","year":"2011"},{"key":"B5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/508024a","article-title":"Cancer treatment: the killer within","volume":"508","author":"Ledford","year":"2014","journal-title":"Nature."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"B12","first-page":"360","article-title":"Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB","volume-title":"Br J Haematol.","author":"Li","year":"2018"},{"key":"B13","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J Hematol."},{"key":"B14","first-page":"1165","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume-title":"Blood.","author":"Haso","year":"2013"},{"key":"B15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4049\/jimmunol.170.1.73","article-title":"CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals","volume":"170","author":"Otero","year":"2003","journal-title":"J Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S1074-7613(02)00426-0","article-title":"The physiologic role of CD19 cytoplasmic tyrosines","volume":"17","author":"Wang","year":"2002","journal-title":"Immunity."},{"key":"B17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: leukemia escape after CD19-directed T Cell immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR-T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1182\/blood-2018-99-115351","article-title":"Aged CAR T cells exhibit enhanced cytotoxicity and effector function but shorter persistence and less memory-like phenotypes","volume":"132","author":"Kotani","year":"2018","journal-title":"Blood."},{"key":"B20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1189\/jlb.5HI0716-322RR","article-title":"Frontline science: functionally impaired geriatric CAR-T cells rescued by increased \u03b15\u03b21 integrin expression","volume":"102","author":"Guha","year":"2017","journal-title":"J Leukoc Biol."},{"key":"B21","article-title":"Starting T cell and cell product phenotype are associated with durable remission of leukemia following CD19 CAR-T cell immunotherapy","volume-title":"Blood.","author":"Gardner","year":"2018"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1101\/gad.278424.116","article-title":"Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis","volume":"30","author":"Inoue","year":"2016","journal-title":"Genes Dev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokinerelease syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood."},{"key":"B30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/0145-2126(92)90153-X","article-title":"Interleukin 6 induces myeloid differentiation of a human biphenotypic leukemic cell line","volume":"16","author":"Cohen","year":"1992","journal-title":"Leuk Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","article-title":"IL-6 controls leukemic multipotent progenitor cell fate and contributes to Chronic myelogenous leukemia development","volume":"20","author":"Reynaud","year":"2011","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"S221","DOI":"10.21037\/tcr.2016.08.15","article-title":"Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy","volume":"5","author":"Perna","year":"2016","journal-title":"Transl Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/bjh.15812","article-title":"Phenotype switch in acute lymphoblastic leukaemia associated with 3 years of persistent CAR T cell directed-CD19 selective pressure","volume":"186","author":"Lucero","year":"2019","journal-title":"Br J Haematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/ni0903-815","article-title":"What is trogocytosis and what is its purpose?","volume":"4","author":"Joly","year":"2003","journal-title":"Nat Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature."},{"key":"B36","doi-asserted-by":"publisher","first-page":"96976","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood."},{"key":"B38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest."},{"key":"B40","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"40272","DOI":"10.1038\/srep40272","article-title":"Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients","volume":"7","author":"Su","year":"2017","journal-title":"Sci Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3389\/fimmu.2017.01850","article-title":"Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications","volume":"8","author":"Mirzaei","year":"2017","journal-title":"Front Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/eji.201344413","article-title":"Inhibitory receptors as targets for cancer immunotherapy","volume":"45","author":"Turnis","year":"2015","journal-title":"Eur J Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.4049\/jimmunol.1100038","article-title":"Inhibitory receptors on lymphocytes: insights from infections","volume":"188","author":"Odorizzi","year":"2012","journal-title":"J Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"Exp Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature."},{"key":"B49","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.18632\/oncotarget.15218","article-title":"A versatile system for rapid multiplex genome-edited CAR T cell generation","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e64138","DOI":"10.1371\/journal.pone.0064138","article-title":"Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells","volume":"8","author":"Singh","year":"2013","journal-title":"PLoS ONE."},{"key":"B51","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1089\/hum.2011.167","article-title":"Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies","volume":"23","author":"Kebriaei","year":"2012","journal-title":"Hum Gene Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1158\/0008-5472.CAN-10-3843","article-title":"Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies","volume":"71","author":"Singh","year":"2011","journal-title":"Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4172\/2169-0111.1000130","article-title":"Artificial antigen presenting cells: an off the shelf approach for generation of desirable T-cell populations for broad application of adoptive immunotherapy","volume":"4","author":"Hasan","year":"2015","journal-title":"Adv Genet Eng."},{"key":"B54","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/mt.2014.148","article-title":"T-cell immunotherapy: looking forward","volume":"22","author":"Corrigan-Curay","year":"2014","journal-title":"Mol Ther."},{"key":"B56","first-page":"3312","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date","volume-title":"Blood.","author":"Park","year":"2016"},{"key":"B57","doi-asserted-by":"publisher","first-page":"33961","DOI":"10.18632\/oncotarget.5582","article-title":"Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget."},{"key":"B58","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1182\/blood.V126.23.183.183","article-title":"Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas","volume":"126","author":"Schuster","year":"2015","journal-title":"Blood."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00262-018-2155-7","article-title":"Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia","volume":"67","author":"Blaeschke","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood."},{"key":"B61","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1056\/NEJMc1808251","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"379","author":"Yang","year":"2018","journal-title":"N Engl J Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJMc1510353","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"373","author":"Asaoka","year":"2015","journal-title":"N Engl J Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JCO.2017.35.15_suppl.103","article-title":"The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL)","volume":"35","author":"Maude","year":"2017","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood."},{"key":"B66","doi-asserted-by":"publisher","first-page":"E340","DOI":"10.3390\/ijms19020340","article-title":"Incorporation of immune checkpoint blockade into chimeric antigen receptor T Cells (CAR-Ts): combination or built-in CAR-T","volume":"19","author":"Yoon","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A Phase 2 trial of ponatinib in philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome\u2013positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"","journal-title":"J Clin Oncol. ("},{"key":"B69","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","article-title":"Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia","volume":"17","author":"Assi","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B70","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000495558","article-title":"Relapsed philadelphia chromosome-positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy successfully treated with combination of Blinatumomab and Ponatinib","volume":"141","author":"El Chaer","year":"2019","journal-title":"Acta Haematol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest."},{"key":"B72","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both cd19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther Oncolytics."},{"key":"B73","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1182\/blood-2018-99-113126","article-title":"Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia","volume":"132","author":"Gardner","year":"2018","journal-title":"Blood."},{"key":"B74","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1182\/blood-2018-99-114415","article-title":"A feasibility and safety study of CD19 and CD22 chimeric antigen receptors-modified T cell cocktail for therapy of B cell acute lymphoblastic leukemia","volume":"132","author":"Yang","year":"2018","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1182\/blood-2018-99-118616","article-title":"Simultaneous targeting of CD19 and CD22: phase I study of AUTO3, a bicistronic chimeric antigen receptor (CAR) T-cell therapy, in pediatric patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (r\/r B-ALL): Amelia study","volume":"132","author":"Amrolia","year":"2018","journal-title":"Blood."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: A Novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol Ther Nucleic Acids."},{"key":"B77","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B Cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"Schneider","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B79","first-page":"4614","article-title":"Targeting primary pre-B cell Acute Lymphoblastic Leukemia and CD19-negative relapses using trivalent CAR T cells","volume":"130","author":"Fousek","year":"2017","journal-title":"Blood."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood.V87.3.1134.bloodjournal8731134","article-title":"Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood Acute Lymphoblastic Leukemias with t(4; 11)(q21; q23) or t(11; 19)(q23; p13) and MLL gene rearrangements","volume":"87","author":"Behm","year":"1996","journal-title":"Blood."},{"key":"B81","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1182\/blood.V89.10.3801","article-title":"MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia","volume":"89","author":"Hilden","year":"1997","journal-title":"Blood."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/sj.leu.2402989","article-title":"Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10\u2212\/CD24\u2212\/CD65s+\/CD15+ B-cell phenotype","volume":"17","author":"Schwartz","year":"2003","journal-title":"Leukemia."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood.V87.3.1123.bloodjournal8731123","article-title":"The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23","volume":"87","author":"Smith","year":"1996","journal-title":"Blood."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/sj.leu.2401840","article-title":"Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1","volume":"14","author":"Wuchter","year":"2000","journal-title":"Leukemia."},{"key":"B85","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fped.2017.00004","article-title":"MLL-rearranged leukemias-an update on science and clinical approaches","volume":"5","author":"Winters","year":"2017","journal-title":"Front Pediatr."},{"key":"B86","doi-asserted-by":"publisher","first-page":"530","DOI":"10.7150\/thno.10824","article-title":"Theranostic impact of NG2\/CSPG4 proteoglycan in cancer","volume":"5","author":"Nicolosi","year":"2015","journal-title":"Theranostics."},{"key":"B87","doi-asserted-by":"publisher","first-page":"E2764","DOI":"10.3390\/ijms20112764","article-title":"CSPG4-specific CAR T cells for high-risk childhood B cell precursor leukemia","volume":"20","author":"Harrer","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1126\/science.1061965","article-title":"BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF","volume":"293","author":"Thompson","year":"2001","journal-title":"Science"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1182\/blood-2006-03-011031","article-title":"Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells","volume":"108","author":"Lee","year":"2006","journal-title":"Blood."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/1535-7163.MCT-13-1023","article-title":"Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R","volume":"13","author":"Parameswaran","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"eaaw9414","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci Transl Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/345074a0","article-title":"The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion","volume":"345","author":"Stamenkovic","year":"1990","journal-title":"Nature."},{"key":"B93","doi-asserted-by":"publisher","first-page":"E352","DOI":"10.1002\/ajh.25235","article-title":"Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia","volume":"93","author":"Rosenthal","year":"2018","journal-title":"Am J Hematol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3389\/fimmu.2018.02235","article-title":"CD22: a regulator of innate and adaptive B cell responses and autoimmunity","volume":"9","author":"Clark","year":"2018","journal-title":"Front Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1084\/jem.173.1.137","article-title":"cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions","volume":"173","author":"Wilson","year":"1991","journal-title":"J Exp Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41467-017-00836-6","article-title":"Molecular basis of human CD22 function and therapeutic targeting","volume":"8","author":"Ere\u00f1o-Orbea","year":"2017","journal-title":"Nat Commun."},{"key":"B97","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med."},{"key":"B98","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.V130.Suppl_1.846.846","article-title":"Sequential infusion of anti-CD22 and Anti-CD19 chimeric antigen receptor T cells for adult patients with refractory\/relapsed B-cell acute lymphoblastic leukemia","volume":"130","author":"Huang","year":"2017","journal-title":"Blood."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2018-99-113714","article-title":"CAR22\/19 cocktail therapy for patients with refractory\/relapsed B-cell malignancies","volume":"132","author":"Huang","year":"2018","journal-title":"Blood."},{"key":"B100","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/cncr.30264","article-title":"Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"123","author":"Jabbour","year":"2017","journal-title":"Cancer."},{"key":"B101","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.bbmt.2017.01.067","article-title":"Phase I trial of total marrow and lymphoid irradiation transplantation conditioning in patients with relapsed\/refractory acute leukemia","volume":"23","author":"Stein","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia."},{"key":"B103","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.bbmt.2017.12.018","article-title":"Chimeric antigen receptor T-Cell (CAR-T) therapy can render patients with ALL into PCR-negative remission and can be an effective bridge to transplant (HCT)","volume":"24","author":"Haneen","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B105","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1182\/blood.V126.23.682.682","article-title":"Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19-Targeted 19-28z CAR modified t cells in adult patients with relapsed, refractory B-cell ALL","volume":"126","author":"Park","year":"2015","journal-title":"Blood."},{"key":"B106","doi-asserted-by":"publisher","first-page":"E155","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: more than ease of access?","volume":"7","author":"Graham","year":"2018","journal-title":"Cells."},{"key":"B107","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/bjh.14923","article-title":"Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation","volume":"179","author":"Chen","year":"2017","journal-title":"Br J Haematol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02664\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T08:40:48Z","timestamp":1664872848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02664\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":107,"alternative-id":["10.3389\/fimmu.2019.02664"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02664","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,12]]},"article-number":"2664"}}